Johnson & Johnson ends partnership with Bavarian Nordic on hepatitis B and HPV vaccines
- Blood drop detection of miRNAs can diagnose early lung cancer
- Will people be arrested if refusing treatment after contracting tuberculosis?
- Vitamin D supplementation may help strengthen Long-COVID recovery
- What bacteria and viruses can cause cancers?
- The world first TIL cell therapy targeting advanced melanoma is coming soon
- The Pros and Cons of Radiotherapy Affecting Antitumor Immunity
Johnson & Johnson ends partnership with Bavarian Nordic on hepatitis B and HPV vaccines
- Hmpv is raging across the United States and the death rate is as high as 43%!
- COVID “Arcturus” XBB.1.16: The first death in U.S.
- The first DMD gene therapy SRP-9001 may cost 4 million US dollars
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- How long can the patient live after heart stent surgery?
Johnson & Johnson ends partnership with Bavarian Nordic on hepatitis B and HPV vaccines
On May 9, Johnson & Johnson announced that it had terminated its partnership and licensing agreement with Bavarian Nordic.
The main content of the agreement is to use Bavarian Nordic’s MVA-BN technology to develop potential vaccines against hepatitis B virus and human papilloma virus. Currently, J&J has not used the technology to develop a hepatitis B vaccine.
For hepatitis B, Johnson & Johnson will continue to prioritize the use of its technology platform to develop related therapeutic drugs. Because hepatitis B remains a serious health problem, about 296 million people worldwide are affected by the disease, and nearly 900,000 people die from it every year.
For human papillomavirus, J&J does not intend to focus its research on its therapeutic vaccine because a preventive vaccine is already widely used.
However, J&J’s collaboration with the company on HIV and Ebola is still ongoing.
(source:internet, reference only)
Disclaimer of medicaltrend.org
